EP1608345A1 - Capsules pour administration orale a action retardee du contenu de la capsule - Google Patents

Capsules pour administration orale a action retardee du contenu de la capsule

Info

Publication number
EP1608345A1
EP1608345A1 EP04724576A EP04724576A EP1608345A1 EP 1608345 A1 EP1608345 A1 EP 1608345A1 EP 04724576 A EP04724576 A EP 04724576A EP 04724576 A EP04724576 A EP 04724576A EP 1608345 A1 EP1608345 A1 EP 1608345A1
Authority
EP
European Patent Office
Prior art keywords
gelatin capsules
oil
capsule
capsules according
capsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04724576A
Other languages
German (de)
English (en)
Inventor
Joachim Herrmann
Karl-Heinz Stumpf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Willmar Schwabe GmbH and Co KG
Original Assignee
Bioplanta Arzneimittel GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioplanta Arzneimittel GmbH filed Critical Bioplanta Arzneimittel GmbH
Publication of EP1608345A1 publication Critical patent/EP1608345A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Definitions

  • the present invention relates to gelatin capsules with delayed release of the capsule content for use as an oral dosage form for food supplements, diatetics and medicaments, the delay in the release being brought about by a plant extract contained in the capsule.
  • the active ingredient is only released from the dosage form a certain time after ingestion or in a certain section of the gastrointestinal tract.
  • the aim of this temporally or locally controlled release is either to protect the user from the unpleasant properties of the active ingredient (eg bad taste, mucous membrane irritant effect, unpleasant eructation) or to protect the active ingredient from being destroyed by the aggressive gastric juice or to improve absorption to achieve the active ingredients in the body through release in the small intestine.
  • This delayed release is particularly desirable when the active ingredients to be applied are pear extracts which, if the capsule disintegrates too quickly, result in an unpleasant taste or smell when belching open or contain substances which can be broken down in the stomach.
  • a preferred dosage form for these food supplements, diatetics and pharmaceuticals is the capsule, which can be filled with liquid, semi-solid or solid substances and whose shell mostly consists of gelatin.
  • Soft gelatin capsules are particularly suitable because they are manufactured, filled and sealed in one step, the capsule contents are well protected against environmental influences such as moisture and oxygen and because these capsules are very easy to take.
  • EP 0243930 B1 describes a gelatin-encapsulated composition with controlled release, consisting of a solid matrix, which is formed from a liquid filling of a vegetable gum and the active ingredient by adding cations.
  • a disadvantage of this type of process is that additional special auxiliaries have to be added to the capsule filling compound in order to obtain a matrix which controls the release.
  • Preparations and processes are used far more frequently in which the release is achieved by changing the capsule shell, either adding substances to the capsule shell material or applying a functional coating to the finished capsule.
  • An example of controlling the release by means of additives to the capsule shell material is EP 0240581 B1, in which physiologically and toxicologically harmless aldehydes with at least 4 carbon atoms are added to the gelatin brew and the brew is further processed into capsules in a manner known per se.
  • a disadvantage of this method is that additional substances have to be introduced into the capsule shell, which can have an undesirable influence on the properties of the capsule or the encapsulated ingredients.
  • EP 1091659 B1 describes a special embodiment of these aldehyde-hardened gelatin capsules, in which finished capsules are sprayed with a solution of xylose, ethanol and water using heat and then heat-treated for a certain period of time. This process is technically and time-consuming, since the solvent used must be removed almost completely during the process and ethanol can only be used as a flammable organic solvent under special technical conditions.
  • polymers are used which are insoluble in strongly acidic gastric juice, but soluble in almost neutral intestinal juice (ie from approx. PH 5-6).
  • suitable poly- mers eg hydroxypropylmethyl cellulose phthalate
  • this solution applied to the capsules in a rotating kettle or a coater.
  • the solvent is evaporated by large amounts of heated air and the precipitated polymer forms a coating on the capsules. This process is technically and time-consuming.
  • the object of the present invention is therefore to influence the disintegration of capsules and the release of the capsule contents during oral administration in a new, simplified and safe form.
  • polyphenols includes simple phenol carboxylic acids such as. As gentisic acid, protocatechic acid, gallic acid or caffeic acid, flavones such as. B. camphor oil, quercetin, myricetin, isomamnetin, naringenin, 6-prenylnaringenin, 8-prenylnaringenin, isoxanthohumol and their glycosides, chalcones such as ⁇ . B. xanthohumol, isoflavones such as.
  • anthocyanins such as. As pelargonidine, cyanidine, malvidin or delphinidine, tanning agents such as. B. catechin and epicatechin and their oligomers and polymers.
  • Camellia sinensis Crataegus monogyna, Ginkgo biloba, Humulus lupulus, Hypericum perforatum, Krameria triandra, Potentilla tormantilla, Pterocarpus marsupium, Quercus species, Uncaria gambir, Vaccinitis myrtle vinifera.
  • polyphenol-containing plant extracts are now used for the first time in order to specifically influence the release of active ingredients from gelatin capsules, this type of decay delay being able to be used with all capsule materials which show an interaction with polyphenols in the manner described.
  • Another advantage of these preparations is that the plant extract used is at the same time one of the active ingredients to be applied, i.e. no additional additives such as Coating, hardening or thickening agents are added to achieve the sustained release.
  • the extracts are filled into the capsules with lipophilic, water-immiscible liquid carriers such as e.g. Mixed vegetable oils.
  • lipophilic, water-immiscible liquid carriers such as e.g. Mixed vegetable oils.
  • This flowable mixture is well suited for filling in capsules.
  • other substances such as Partially or fully hydrogenated vegetable oils, beeswax, lecithin, neutral oil, hard fat and highly disperse silicon dioxide are added to the capsule filling mass in order to adjust the consistency of the mixture and to prevent separation of the liquid carrier and solid plant extract.
  • amphiphilic, surface-active substances and emuigators such as e.g. Sorbitan monooleate can be added.
  • the extracts can be prepared in a variable composition with solvents such as e.g. B. water, methanol, ethanol, 2-propanol, acetone, etc. and their mixtures, at temperatures of room temperature. up to 100 ° C with gentle to vigorous mixing or by percolation within 10 minutes to 24 hours under normal pressure or increased pressure.
  • solvents such as e.g. B. water, methanol, ethanol, 2-propanol, acetone, etc. and their mixtures
  • further concentration steps can be carried out, e.g. B. liquid liquid distribution with z. B. 1-butanol / water or ethyl acetate / water, adsorption-desorption on ion exchanger, LH20, HP20 and other resins or chromatographic separations over RP18, silica gel, etc.
  • the further processing to dry extracts is carried out according to known methods by removing the solvent increased temperature and / or reduced pressure.
  • a particularly preferred embodiment of the capsules with delayed disintegration is the combination of a polyphenol-containing plant extract and an oil with a high content of omega-3 fatty acids, in particular periila seed oil, evening primrose seed oil, currant seed oil, fish oil, borage oil or linseed oil, because both the polyphenol-containing plant extracts and those mentioned Vegetable oils favorably influence chronic inflammatory or immunological diseases and fat metabolism disorders.
  • Gelatin capsules containing one of the following combinations are preferred: extract from Vitis vinifera (grape seed extract, ie extract from seeds of red and / or white grapes) and periila seed oil, extract from Vitis vinifera (red wine extract, ie extract from red grapes) and periilase seed oil, extract from Potentilla tormentilla and linseed oil, extract from Crataegus monogyna and linseed oil, extract from Camellia sinensis and borage oil, extract from Ginkgo biloba and borage oil, extract from Krameria triandra and evening primrose oil, extract from Vaccinium myrtillus and evening primrose oil, extract from hyper extract Humulus lupulus and fish oil, extract from Uncaria gambir and currant seed oil, extract from Quercus and currant seed oil, extract from Pterocarpus marsupium and Periilasamenöl, extract from Camellia sinensis and Periilasa
  • the delay in the release of active ingredient is independent of whether the gelatin capsules are hard or soft gelatin capsules, since these differ only in the plasticizer and water content.
  • Example 1 the gelatin capsules are hard or soft gelatin capsules, since these differ only in the plasticizer and water content.
  • Periila seed oil (75 parts) is mixed with hard fat (12 parts) and heated to 40 ° C with stirring.
  • Granular silica (5 parts) and grape seed extract (8 parts) are added to the liquid phase and distributed with stirring.
  • 0.6 g of the suspension obtained are filled into a gelatin capsule. The sealed capsules are stored at an elevated temperature.
  • the capsules containing grape seed extract show a prolonged disintegration time in the disintegration test in artificial gastric juice compared to the capsules that do not contain grape seed extract.
  • Periila seed oil (69 parts) is mixed with hard fat (11 parts) and heated to 40 ° C with stirring. Highly disperse silicon dioxide (5 parts) and red wine extract (15 parts) are added to the liquid phase and distributed with stirring. Each 0.65 g of the suspension obtained is filled into a gelatin capsule. The sealed capsules are stored at an elevated temperature.
  • the capsules containing red wine extract show a prolonged disintegration time when tested in artificial gastric juice compared to capsules that do not contain red wine extract.
  • the initial value for the capsule opening time before incubation at elevated temperature / humidity was 4 min. Without the addition of the polyphenol-containing plant extract, the disintegration time remains unchanged even when stored; the addition of the plant extract and storage increases the disintegration time of the capsules. Storage in the absence of water vapor leads to a longer increase in the decay time.
  • the disintegration time of soft gelatin capsules can thus be influenced in a targeted manner, as has been shown on two capsule batches which contain two different batches of the red wine extract.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne des capsules de gélatine à action retardée du contenu de la capsule, prévues pour être administrées par voie orale et destinées à des compléments alimentaires, des produits diététiques et des médicaments, le retardement de la libération étant provoqué par un extrait végétal contenu dans la capsule.
EP04724576A 2003-04-02 2004-03-31 Capsules pour administration orale a action retardee du contenu de la capsule Withdrawn EP1608345A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2003115027 DE10315027A1 (de) 2003-04-02 2003-04-02 Kapseln mit verzögerter Freisetzung des Kapselinhaltes zur oralen Verabreichung
DE10315027 2003-04-02
PCT/EP2004/003400 WO2004087114A1 (fr) 2003-04-02 2004-03-31 Capsules pour administration orale a action retardee du contenu de la capsule

Publications (1)

Publication Number Publication Date
EP1608345A1 true EP1608345A1 (fr) 2005-12-28

Family

ID=32980962

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04724576A Withdrawn EP1608345A1 (fr) 2003-04-02 2004-03-31 Capsules pour administration orale a action retardee du contenu de la capsule

Country Status (3)

Country Link
EP (1) EP1608345A1 (fr)
DE (1) DE10315027A1 (fr)
WO (1) WO2004087114A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10315025A1 (de) * 2003-04-02 2004-10-14 Bioplanta Arzneimittel Gmbh Wirkstoffkombination von ω3-fettsäurehaltigen Ölen mit polyphenolhaltigen Pflanzenextrakten und deren Verwendung
WO2006092295A1 (fr) * 2005-03-02 2006-09-08 Kairosmed Gmbh Formulations orales a liberation modifiee contenant de la 8-prenylnaringenine pour un soutien estrogenique continu
EP1698332A1 (fr) * 2005-03-02 2006-09-06 KAIROSmed GmbH Compositions orales à libération modifiée contenant le composé 8-prénylnaringénine pour une substitution estrogénique continue
CN107712902A (zh) * 2017-11-23 2018-02-23 甘肃省徽县雅龙银杏产业开发有限责任公司 一种含银杏果和橄榄油的保健品及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1011265A (en) * 1961-09-25 1965-11-24 Takeda Chemical Industries Ltd A process for the preparation of a medicinal agent for the treatment of hypercholesterolemia from the oil of marine animals
JPH02243622A (ja) * 1989-03-16 1990-09-27 Nippon Oil & Fats Co Ltd 血中コレステロール低下用油脂組成物
FR2673513B1 (fr) * 1991-03-05 1993-10-29 Institut Recherche Biologique Sa Nouvelles compositions dietetiques a base de lipides phosphoryles et leur utilisation dans l'amelioration des troubles de la vision.
IT1255029B (it) * 1992-05-11 1995-10-13 Paolo Morazzoni Formulazioni farmaceutiche orali contenenti antocianosidi
US5955102A (en) * 1998-09-04 1999-09-21 Amway Corporation Softgel capsule containing DHA and antioxidants
CN1279072A (zh) * 2000-07-03 2001-01-10 高林 一种防治心脑血管病的药物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004087114A1 *

Also Published As

Publication number Publication date
WO2004087114A1 (fr) 2004-10-14
DE10315027A1 (de) 2004-10-14

Similar Documents

Publication Publication Date Title
Ribeiro et al. Microencapsulation of polyphenols-The specific case of the microencapsulation of Sambucus Nigra L. extracts-A review
ES2924255T3 (es) Extracto vegetal altamente concentrado en safranal, método de producción y usos del mismo
DE4434170C1 (de) Johanniskrautextrakte
Udapurkar et al. Phyto-phospholipid complex vesicles for phytoconstituents and herbal extracts: A promising drug delivery system
JP2818220B2 (ja) 食品用の含水有機溶剤抽出物含有組成物および医薬用の含水有機溶剤抽出物含有組成物、並びにそれらの製造方法
Anjana et al. Phytosome drug delivery of natural products: A promising technique for enhancing bioavailability
EP1608387A2 (fr) COMBINAISONS DE PRINCIPES ACTIFS D'HUILES CONTENANT DES ACIDES GRAS w3 AVEC DES EXTRAITS VEGETAUX CONTENANT DES POLYPHENOLS ET UTILISATION DESDITES COMBINAISONS
Yeop et al. Stability and controlled release enhancement of Labisia pumila's polyphenols
Pham et al. Controlled-Release Wedelia trilobata L. Flower Extract Loaded Fibroin Microparticles as Potential Anti-Aging Preparations for Cosmetic Trade Commercialization
Avanço et al. Preparation and characterisation of ethylcellulose microparticles containing propolis
JPH0665042A (ja) 皮膚外用剤
EP1608345A1 (fr) Capsules pour administration orale a action retardee du contenu de la capsule
Deshpande et al. Phytosomes: A noval drug delivery system for phytoconstituents
EP1608386B1 (fr) Utilisation des huiles contenant des acides gras omega-3 et pour ameliorer la biodisponibilite des extraits vegetaux
AU2017322712B2 (en) Odor masking formulations for natural compounds
EP1682162A1 (fr) Utilisation de fragments vegetaux et/ou d'extraits de figue de barbarie (opuntia) pour traiter des depressions
FR3064180A1 (fr) Formulations comprenant des actifs issus de la plante murraya koenigii
EP0620727A1 (fr) Elements fa onnes, notamment comprimes, contenant des extraits de plantes, et leur application pharmaceutique ou cosmetique.
DE19845246A1 (de) Vitaminhaltige Zubereitungen
EP1599211B1 (fr) Utilisation d'isorhamnetine pour traiter des etats depressifs et la depression
Herman-Lara et al. Encapsulation of hydroalcoholic extracts of Moringa oleifera seed through ionic gelation
IT202100022979A1 (it) Composizione contenente polifenoli ad elevata biodisponibilità
Kumari et al. PHYTOSOMES: A NOVEL DRUG DELIVERY SYSTEM FOR POLY-PHENOLIC PHYTO-CONSTITUENTS
Khan et al. A Study on Phytochemical and Antioxidant properties of the Leaves of Ficus hispida Linn.
BR102021006994A2 (pt) Produtos secos nanodispersos a partir de calophyllum brasiliense cambés: processo de obtenção e utilidade farmacológica e cosmética.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050927

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DR. WILLMAR SCHWABE GMBH & CO. KG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20101214